Hasnaà Haddouk

Hasnaà Haddouk currently serves as VP and Head of Preclinical Development & Translational Medicine at Sobi - Swedish Orphan Biovitrum AB (publ) since July 2019, having previously held the position of Head of Bioanalytical Sciences & Non Clinical Safety Immunology. Prior experience includes Head of Non Clinical Safety at NovImmune, and roles in toxicology and safety assessment at AC Immune and Addex Therapeutics. A consultant for biotech companies and non-profit foundations from 2013 to 2015, Hasnaà also worked at CiToxLAB as Head of Short-Term, Local Tolerance and in vitro Toxicology, and Head of Genetic Toxicology. Hasnaà holds a PhD in Toxicology from Bordeaux University and is a Diplomate of the American Board of Toxicology, as well as possessing a Regulatory Affairs Dual Certificate in Pharmaceuticals and Medical Devices.